Corcept Therapeutics (CORT) Cost of Revenue (2012 - 2026)

Corcept Therapeutics (CORT) has 15 years of Cost of Revenue data on file, last reported at $2.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 19.98% year-over-year to $2.9 million; the trailing twelve-month figure through Mar 2026 stood at $13.5 million (up 25.18% YoY), and the FY2025 full-year result was $13.0 million, up 19.25% from the prior year.
• Cost of Revenue grew to $2.9 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $4.6 million in Q3 2025 to a low of $1.2 million in Q1 2022.
• A 5-year average of $2.3 million and a median of $2.4 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 82.9% in 2024 and decreased 13.9% in 2025, its largest moves.
• Tracing CORT's Cost of Revenue over 5 years: stood at $1.5 million in 2022, then rose by 26.82% to $1.9 million in 2023, then jumped by 57.49% to $3.0 million in 2024, then declined by 13.9% to $2.5 million in 2025, then gained by 13.28% to $2.9 million in 2026.
• Business Quant data shows CORT's Cost of Revenue at $2.9 million in Q1 2026, $2.5 million in Q4 2025, and $4.6 million in Q3 2025.